Article

Blackstone is creating a publicly traded platform for AI data center investments, targeting capital from sovereign wealth and institutional investors. The firm is also competing with Brookfield Asset Management for a controlling stake in Volkswagen's Everllence SE division, alongside other bidders.

Additionally, Blackstone Life Sciences has partnered with Johnson & Johnson to co-fund the clinical progression of an experimental leukemia treatment. RBC Capital initiated coverage of Blackstone with an Outperform rating and a $179 price target.